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Emerging challengers in knowledge-based industries?  




The growth of outward foreign direct investment (FDI) from developing countries and of a 
new generation of “emerging multinational enterprises” (EMNEs) has stimulated a flurry of 
publications. EMNEs have been portrayed as on their way to adulthood, latecomers that 
leapfrog into advanced positions, emerging giants, and challengers of conventional 
multinational enterprises (MNEs) from advanced economies. 
 
While some EMNE FDI can be classified as resource-seeking, often by state-owned 
enterprises, an increasing number of EMNEs, often in private hands, operate in knowledge-
based industries. Most EMNEs in knowledge-based industries (KB EMNEs) are 
headquartered in India or China. They have tended to pursue interrelated asset-augmenting 
and market-seeking strategies in North America and Europe.  
 
While much research has been devoted to KB EMNE’s internationalization and resource-
building, the particular structural characteristics of industries in which these operate have 
been neglected. As the case of Indian pharmaceutical companies demonstrates, the latter 
factor plays a significant role in whether and how fast KB EMNEs can close the gap with 
their competitors from advanced economies.1 
 
Some of the more prominent Indian pharmaceutical companies, such as Ranbaxy or Dr. 
Reddy’s Limited (DRL), have been cited as instances of a leapfrogging internationalization 
trajectory leading to fast catch-up in competitiveness with conventional MNEs. However, a 
closer look at the global pharmaceutical industry reveals a vast scale-gap between Indian 
pharmaceutical companies and major conventional pharmaceutical companies (“Big Pharma”) 
(see table 1 on the website version of this Perspective). In 2009, DRL, India’s leading 
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pharmaceutical company by worldwide revenues, was not ranked among the global top 50 
pharma companies. DRL’s worldwide revenues of US$ 1.5 billion fell far short of the US$ 45 
billion generated by the market leader Pfizer (USA) or the US$ 37.6 billion by the Swiss 
company Roche, ranked fifth, and are still less than the US$ 1.7 billion achieved by the 
Swedish Meda company, placed 50th.  
 
Research and development (R&D) expenditure is a more specific indicator of global 
competitive resources. In a lengthy and risky process, more than US$ 1 billion are usually 
required to bring a new drug to market (see table 2 on the website version of this Perspective). 
Indian pharmaceutical companies spend far less than Big Pharma. The 2009 research 
spending of US$ 99 million (Ranbaxy), US$ 89 million (DRL) and US$ 67 million (Sun 
Pharma) compares with US$ 8,570 million by the largest spender, Roche, US$ 6,286 million 
for the fifth largest (GlaxoSmithKline), and are still only roughly half of the 50th in the global 
ranking (Watson, a generics company). 
 
In addition to critical mass in R&D, other factors such as a worldwide sales force, 
relationships with key opinion leaders, worldwide regulatory experience, and ownership of 
intellectual assets present formidable entry barriers into the research-based segment which 
still dominates the more than US$ 800 billion global pharmaceutical market. Given the 
valuations of Big Pharma firms, overcoming entry barriers via acquisitions does not seem to 
be a feasible pathway for Indian pharmaceutical companies. 
 
In view of these barriers Indian pharmaceutical companies pursue more modest upgrading 
internationalization strategies. Based on location-specific cost advantages and reverse 
engineering, their FDI is primarily aimed at building international positions as generics 
(imitator) companies, often by acquiring smaller generics players in the US and Europe. So 
far they have not yet achieved leading positions in the global generics market partly due to 
rapid market consolidation and the increasing entry of Big Pharma. Most major Indian 
pharmaceutical companies have also engaged in manufacturing and R&D outsourcing for Big 
Pharma, exploiting growth and learning opportunities. 
 
Although leading Indian pharmaceutical companies such as DRL or Lupin Labs have invested 
in high-risk discovery research with some success, the enormous costs and risks of global 
development have often led to partnering with Big Pharma. In view of the considerable 
barriers and uncertain outcomes, a number of family-owned Indian pharmaceutical companies 
have sold out to Big Pharma in recent years. This sale of India’s crown jewels has prompted 
consideration in Indian Government circles of restrictions on inward FDI in the 
pharmaceutical industry and led to calls for industry consolidation. 
 
In comparing Indian pharmaceutical companies with other Indian and Chinese knowledge-
based EMNEs, it may be useful to distinguish two extremes on a continuum. At one end, there 
are leapfrogging industries such as telecommunications equipment and IT services, in which 
knowledge-based EMNEs have captured globally competitive positions in relatively shorter 
time spans (Huawei or Tata Consultancy Services are prominent examples). At the other end, 
we have “fortress industries” such as pharmaceuticals, packaged software or certain branded 
consumer goods segments where, due to the interaction of global oligopolistic structures, 
complex and multiple complementary resource and capability requirements or intellectual 
property and brand walls, the catch-up process – if left to market forces – may take much 
longer.  
 
Emerging market government policies may influence this scenario. Massive support of 
selected state-owned champions may support a faster “invasion” into fortress industries, as the 
examples of China in wide-bodied aircraft or high-speed trains may indicate. Governments 
may also pursue infant industry protection of national private champions. Both cases raise 







Table 1. Worldwide sales of leading Indian and global pharmaceutical MNEs, FY 2009 



























3 CIPLA 1,158 56.9 10 Bristol-Myers 
Squibb, USA 
18,800 
4 Sun Pharma 974 52.8 25 Mylan, USA 4,800 
 
5 Lupin Labs 842 66.0 50 Meda, SWE 1,700 
 
* Ranbaxy was acquired by Daiichi Sankyo from Japan in March 2009. 
Source: Bruche 2011 (ref. 1). 
 
Table 2. R&D spending of leading Indian and global pharmaceutical MNEs, FY 2009 
Indian pharmaceutical companies Global pharmaceutical companies 
Indian rank in 
R&D 
spending 
Company R&D exp. 
FY 2008/09, 
million US$ 
Global rank in 
R&D 
spending 
Company R&D exp.  
2009, million 
US$ 
1 Ranbaxy* 99 1 Roche, CH 8,570 
2 Dr. Reddy’s 89 5 GlaxoSmithKline, 
UK 
6,286 
3 Sun Pharma 67 10 Elli Lilly, USA 4,300 
4 Cipla 51 25 Lundbeck, DNK 615 
5 Lupin Labs 50 50 Watson, USA 197 
*Ranbaxy was acquired by Daiichi Sankyo from Japan in March 2009. 
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